相似文献
1
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.
Blood Adv. 2023 Jun 13;7(11):2580-2585. doi: 10.1182/bloodadvances.2022007126.
2
Hypoxemia During Extreme Hyperleukocytosis: How Spurious?
Respir Care. 2016 Jan;61(1):8-14. doi: 10.4187/respcare.04196. Epub 2015 Sep 29.
3
[Retinoic acid in treating acute promyelocytic leukemia with hyperleukocytosis and its therapeutic strategy].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr;16(2):439-41.
4
CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis.
Clin Lab Haematol. 2005 Oct;27(5):307-11. doi: 10.1111/j.1365-2257.2005.00715.x.
5
Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia.
Sci Rep. 2019 Aug 15;9(1):11935. doi: 10.1038/s41598-019-47937-4.
6
Acute Budd-Chiari syndrome as an initial presentation of acute promyelocytic leukemia.
J Cancer Res Ther. 2010 Oct-Dec;6(4):567-9. doi: 10.4103/0973-1482.77077.
7
Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis.
J Formos Med Assoc. 2014 Nov;113(11):833-8. doi: 10.1016/j.jfma.2014.01.006. Epub 2014 Feb 15.
8
[Hyperleukocytosis in a variant form of acute promyelocytic leukemia].
Rinsho Ketsueki. 1988 Sep;29(9):1437-41.
9
The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
Leuk Res. 2017 Oct;61:84-88. doi: 10.1016/j.leukres.2017.09.006. Epub 2017 Sep 14.
10
Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.
Transfusion. 2018 May;58(5):1149-1156. doi: 10.1111/trf.14512. Epub 2018 Feb 4.
引用本文的文献
1
Emergencies in Hematology: Why, When and How I Treat?
J Clin Med. 2024 Dec 12;13(24):7572. doi: 10.3390/jcm13247572.
2
Standard dose anthracycline plus all-trans retinoic acid and arsenic trioxide as induction chemotherapy significantly reduces early death and relapse for high-risk acute promyelocytic leukemia: a single-center real-world analysis.
Ther Adv Hematol. 2024 Nov 19;15:20406207241299699. doi: 10.1177/20406207241299699. eCollection 2024.
3
Complete elimination of hyperleukocytosis risk in AML through early high-quality disease remission.
Front Oncol. 2024 Jun 13;14:1412583. doi: 10.3389/fonc.2024.1412583. eCollection 2024.
本文引用的文献
1
Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6). doi: 10.1073/pnas.2020382118.
2
Curative strategies in APL.
Semin Hematol. 2019 Apr;56(2):131-138. doi: 10.1053/j.seminhematol.2018.07.004. Epub 2018 Aug 23.
3
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25.
4
Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab.
Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.
5
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20.
6
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.
7
Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study.
Br J Haematol. 2014 Sep;166(5):660-6. doi: 10.1111/bjh.12931. Epub 2014 Apr 30.
8
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Leuk Lymphoma. 2014 Jul;55(7):1523-32. doi: 10.3109/10428194.2013.842985. Epub 2014 Feb 4.
9
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.
10
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).
Med Oncol. 2012 Sep;29(3):2095-101. doi: 10.1007/s12032-012-0251-7. Epub 2012 May 22.
Zotero 插件